Search

Displaying results 5471 - 5480 of 5758 in total
  1. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs ga...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising telisotuzumab, a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting agent, via a protea...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  3. Drug

    Fluciclovine

    go.drugbank.com/drugs/DB15237
    Investigational

    Fluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).

    Categories: P-glycoprotein inhibitors
  4. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated a...

    Categories: P-glycoprotein substrates
  5. Drug

    beta-Escin

    go.drugbank.com/drugs/DB15774
    Investigational

    Mixtures: Reparil Gel N
  6. Drug

    Fluocortolone pivalate

    go.drugbank.com/drugs/DB15777
    Investigational

    Mixtures: ULTRAPROCT N, ULTRAPROCT N
  7. Drug

    Chamazulene

    go.drugbank.com/drugs/DB15931
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    Cinnamon oil

    go.drugbank.com/drugs/DB15986
    ApprovedInvestigational

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  9. Drug

    JBPOS0101

    go.drugbank.com/drugs/DB16034
    Investigational

    JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  10. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.